OpenURL Connection Search

Select item for more details and to access through your institution.

ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP.
Published in:
Hematological Oncology, 2019, v. 37, p. 37, doi. 10.1002/hon.6_2629
By:
- Nowakowski, G.S.;
- Hong, F.;
- Scott, D.W.;
- Macon, R.;
- King, R.L.;
- Habermann, T.M.;
- Wagner‐Johnston, N.;
- Casulo, C.;
- Wade, J.L.;
- Nagargoje, G.G.;
- Reynolds, C.M.;
- Cohen, J.B.;
- Khan, N.;
- Amengual, J.;
- Richards, K.L.;
- Little, R.F.;
- Leonard, J.P.;
- Friedberg, J.W.;
- Kostakoglu, L.;
- Kahl, B.S.
Publication type:
Article
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP.
Published in:
Hematological Oncology, 2019, v. 37, p. 37, doi. 10.1002/hon.6_2629
By:
- Nowakowski, G.S.;
- Hong, F.;
- Scott, D.W.;
- Macon, R.;
- King, R.L.;
- Habermann, T.M.;
- Wagner‐Johnston, N.;
- Casulo, C.;
- Wade, J.L.;
- Nagargoje, G.G.;
- Reynolds, C.M.;
- Cohen, J.B.;
- Khan, N.;
- Amengual, J.;
- Richards, K.L.;
- Little, R.F.;
- Leonard, J.P.;
- Friedberg, J.W.;
- Kostakoglu, L.;
- Kahl, B.S.
Publication type:
Article
LONG-TERM FOLLOW-UP UPDATE FOR PATIENTS ENROLLED IN ECOG 1405.
Published in:
Hematological Oncology, 2017, v. 35, p. 202, doi. 10.1002/hon.2438_65
By:
- Khan, N.;
- Parekh, S.;
- Perumal, D.;
- Jegede, O.;
- Kahl, B.S.
Publication type:
Article
MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE.
Published in:
Hematological Oncology, 2017, v. 35, p. 216, doi. 10.1002/hon.2438_80
By:
- Pott, C.;
- Belada, D.;
- Danesi, N.;
- Fingerle ‐ Rowson, G.R.;
- Gribben, J.;
- Harbron, C.G.;
- Hoster, E.;
- Kahl, B.S.;
- Kehden, B.;
- Mundt, K.E.;
- Nicolas ‐ Virelizier, E.;
- Sehn, L.H.;
- Cheson, B.D.
Publication type:
Article
THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL.
Published in:
Hematological Oncology, 2017, v. 35, p. 92, doi. 10.1002/hon.2437_81
By:
- Scott, D.W.;
- Li, H.;
- Harvey, Y.;
- Chan, F.;
- Mottok, A.;
- Boyle, M.;
- Evens, A.M.;
- Schoder, H.;
- Straus, D.J.;
- Bartlett, N.L.;
- Sweetenham, J.W.;
- Barr, P.M.;
- Fanale, M.A.;
- Hsi, E.D.;
- Cook, J.R.;
- Kahl, B.S.;
- Leonard, J.P.;
- Friedberg, J.W.;
- Leblanc, M.;
- Steidl, C.
Publication type:
Article

Found: 5

ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP.

ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP.

LONG-TERM FOLLOW-UP UPDATE FOR PATIENTS ENROLLED IN ECOG 1405.

MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE.

THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL.